Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Status:
Terminated
Trial end date:
2017-09-14
Target enrollment:
Participant gender:
Summary
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to
this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or
ADT with Radium-223 dichloride respectively.
Phase:
Phase 2
Details
Lead Sponsor:
Ajjai Alva, MD
Collaborators:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Hoosier Cancer Research Network
Treatments:
Androgens Bicalutamide Radium Ra 223 dichloride Succinylcholine